Clinical data | |
---|---|
Pronunciation | /ˌsɛfəˈtækˌsiːm/[1] |
Trade names | Claforan, others |
Other names | cefotaxime sodium |
AHFS/Drugs.com | Monograph |
MedlinePlus | a682765 |
License data |
|
Pregnancy category |
|
Routes of administration | Intravenous and intramuscular |
ATC code | |
Legal status | |
Legal status |
|
Pharmacokinetic data | |
Bioavailability | n/a |
Metabolism | liver |
Elimination half-life | 0.8–1.4 hours |
Excretion | 50–85% kidney |
Identifiers | |
| |
CAS Number | |
PubChem CID | |
DrugBank | |
ChemSpider | |
UNII | |
KEGG | |
ChEMBL | |
CompTox Dashboard (EPA) | |
ECHA InfoCard | 100.058.436 |
Chemical and physical data | |
Formula | C16H17N5O7S2 |
Molar mass | 455.46 g·mol−1 |
3D model (JSmol) | |
| |
| |
(verify) |
Cefotaxime is an antibiotic used to treat several bacterial infections in humans, other animals, and plant tissue culture.[3] Specifically in humans it is used to treat joint infections, pelvic inflammatory disease, meningitis, pneumonia, urinary tract infections, sepsis, gonorrhea, and cellulitis.[3] It is given either by injection into a vein or muscle.[3]
Common side effects include nausea, allergic reactions, and inflammation at the site of injection.[3] Another side effect may include Clostridioides difficile diarrhea.[3] It is not recommended in people who have had previous anaphylaxis to a penicillin.[3] It is relatively safe for use during pregnancy and breastfeeding.[3][4] It is in the third-generation cephalosporin family of medications and works by interfering with the bacteria's cell wall.[3]
Cefotaxime was discovered in 1976 and came into commercial use in 1980.[5][6] It is on the World Health Organization's List of Essential Medicines.[7] It is available as a generic medication.[3]